Organic bismuth derivatives for X-ray imaging
    1.
    发明授权
    Organic bismuth derivatives for X-ray imaging 失效
    有机铋衍生物用于X射线成像

    公开(公告)号:US5939045A

    公开(公告)日:1999-08-17

    申请号:US860320

    申请日:1997-07-18

    IPC分类号: A61K49/04 C07F9/94

    CPC分类号: C07F9/94 A61K49/04 Y10S424/90

    摘要: An organic bismuth derivative represented by formula (I) or its salt: �wherein X.sup.1 is YNR.sup.1 R.sup.2 (wherein Y is --SO.sub.2 -- or --C(O)--, R.sup.1 is a C.sub.3-6 alkyl group which have from 2 to 5 hydroxyl groups which may be protected, and R.sup.2 is a hydrogen atom, a C.sub.1-6 alkyl group or a C.sub.1-5 acyl group which may have from 1 to 5 hydroxyl groups which may be protected, or R.sup.1 and R.sup.2, together with each other, represent a C.sub.2-6 cyclic alkylene which may have from 1 to 4 hydroxyl groups which may be protected), and each of X.sup.2 and X.sup.3 is, independently of each other, a hydrogen atom, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy group, a C.sub.1-4 alkylsulfonyl group, a C.sub.1-4 alkylcarbonyl group, a nitro group, a cyano group or the same as defined for X.sup.1 !.

    摘要翻译: PCT No.PCT / JP95 / 02551 Sec。 371日期1997年7月18日 102(e)1997年7月18日PCT 1995年12月13日PCT PCT。 WO96 / 19487 PCT出版物 日期:1996年6月27日由式(I)表示的有机铋衍生物或其盐:[其中X1为YNR1R2(其中Y为-SO2-或-C(O) - ,R1为C3-6烷基, 2〜5个可被保护的羟基,R2是氢原子,可以具有1〜5个可被保护的羟基的C1-6烷基或C1-5酰基,或者R1和R2一起 彼此表示可以具有1〜4个可被保护的羟基的C 2-6环状亚烷基,X2和X3各自独立地为氢原子,C1-4烷基, C 1-4烷氧基,C 1-4烷基磺酰基,C 1-4烷基羰基,硝基,氰基或与X 1所定义的相同]。

    4-oxybenzopyran derivative
    3.
    发明授权
    4-oxybenzopyran derivative 失效
    4-羟基苯并吡喃衍生物

    公开(公告)号:US06555574B1

    公开(公告)日:2003-04-29

    申请号:US10049996

    申请日:2002-03-29

    IPC分类号: A61K3135

    CPC分类号: C07D405/12 C07D311/22

    摘要: This invention relates to a 4-oxybenzopyran derivative of formula (I) wherein, R1 and R2 represent each independently a hydrogen atom, a C1-6 alkyl group or a phenyl group; R3 represents a hydroxyl group or a C1-6 alkylcarbonyloxy group; R4 represents a hydrogen atom, a C3-6 cycloalkyl group, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkylaminocarbonyl group, a di-C1-6 alkylaminocarbonyl group, an aryl group or a heteroaryl group; n represents an integer of 0-4; X represents —C(═O)NR7—, —NR8—, —NHC(═O)NH— or —S(O)2NH—; R5 represents a hydrogen atom or (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), or (l); R6 represents a hydrogen atom, a halogen atom, a nitro group or a cyano group; or a pharmaceutically acceptable salt thereof. And this invention also relates to an antiarrhythmic agent having the prolongation effect of the functional refractory period comprising said compound or a pharmaceutically acceptable salt thereof as an active ingredient.

    摘要翻译: 本发明涉及式(I)的4-氧代苯并吡喃衍生物,其中R1和R2各自独立地表示氢原子,C1-6烷基或苯基; R3表示羟基或C1-6烷基羰基氧基; R 4表示氢原子,C 3-6环烷基,C 1-6烷基,C 1-6烷基羰基,C 1-6烷基氨基羰基,二-C 1-6烷基氨基羰基,芳基或杂芳基 ; n表示0-4的整数; X表示-C(= O)NR 7 - , - NR 8 - , - NHC(= O)NH-或-S(O)2 NH-; R5代表氢原子或(a),(b),(c),(d),(e),(f),(g),(h),(i),(j),(k) 或(l); R6表示氢原子,卤素原子,硝基或氰基; 或其药学上可接受的盐。 本发明还涉及具有作为活性成分的所述化合物或其药学上可接受的盐的具有功能性不应期的延长作用的抗心律失常药。

    Chroman derivatives
    4.
    发明授权
    Chroman derivatives 失效
    色原衍生物

    公开(公告)号:US6066631A

    公开(公告)日:2000-05-23

    申请号:US232645

    申请日:1999-01-19

    摘要: The present invention relates to chroman derivatives of the formula (I): ##STR1## [wherin R.sup.1 represents a hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy group, a C.sub.3-6 alkoxymethyl group, etc., R.sup.3 and R.sup.4 each independently represent a hydrogen atom, a C.sub.1-6 alkyl group, etc., R.sup.5 represents a hydroxyl group or a C.sub.1-6 alkylcarbonyloxyl group or forms a bond together with R.sup.5, R.sup.6 represents a hydrogen atom or forms a bond together with R.sup.5, R.sup.7 and R.sup.8 each independently represent a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-6 cycloalkyl group, a phenyl group, etc. n is 0 or an integer of 1, 2, 3 or 4, W represents a phenyl group, etc., X represents C.dbd.O, CH.sub.2, SO.sub.2, etc., Y represents NR.sup.17 (in which R.sup.17 represents a hydrogen atom, a C.sub.1-4 alkyl group, a phenyl group, etc.), etc., Z does not exist or represents CH.sub.2 or NR.sup.18 (R.sup.18 represents a hydrogen atom, a C.sub.1-4 alkyl group, or a phenyl group, etc.)] or their salts.

    摘要翻译: 本发明涉及式(I)的苯并二氢吡喃衍生物:其中R1表示氢原子,卤素原子,C1-6烷基,C1-6烷氧基,C3-6烷氧基甲基等, R 3和R 4各自独立地表示氢原子,C 1-6烷基等,R 5表示羟基或C 1-6烷基羰氧基,或与R 5一起形成键,R 6表示氢原子或者一起形成键 R5,R7和R8各自独立地表示氢原子,C1-6烷基,C3-6环烷基,苯基等,n为0或1,2,3或4的整数,W表示 苯基等,X表示C = O,CH 2,SO 2等,Y表示NR 17(其中R 17表示氢原子,C 1-4烷基,苯基等)等, Z不存在或表示CH2或NR18(R18表示氢原子,C1-4烷基或苯基等)]或其盐。

    Pyrazolones derivatives
    7.
    发明授权
    Pyrazolones derivatives 失效
    吡唑啉酮衍生物

    公开(公告)号:US5968967A

    公开(公告)日:1999-10-19

    申请号:US51085

    申请日:1998-04-13

    摘要: A pyrazolone derivative represented by general formula (I) or a salt thereof: ##STR1## [wherein one of X.sup.1 and X.sup.2 is ##STR2## (wherein A is a cyano group, a cyano C.sub.1-4 alkyl group, an amino group, an amino C.sub.1-4 alkyl group, an amidino group or a guanidino group, R.sup.1 and R.sup.2 are independently hydrogen atoms, halogen atoms, C.sub.1-6 alkyl groups or the like) or the like],the other of X.sup.1 and X.sup.2 is a C.sub.1-6 alkyl group, a C.sub.3-6 alkenyl group, an aryl C.sub.1-4 alkyl group or an aryl group,one of Y.sup.1 and Y.sup.2 is ##STR3## (wherein Q is an oxygen atom or a sulfur atom, Z.sup.1 is an oxygen atom, a --NR.sup.7 -- group or a --CHR.sup.7 -- group, Z.sup.2 is a cyclic C.sub.3-7 alkylene group, a C.sub.1-3 alkylene group, a --CH.sub.2 CO-- group or --CH.sub.2 CH.sub.2 CO-- group, Z.sup.3 is an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group or the like, Z.sup.4 is a C.sub.1-3 alkylene group, and Z.sup.5 is a carboxyl group or the like, andthe other of Y.sup.1 and Y.sup.2 is a D-E- group [wherein E is a bond, a C.sub.1-4 alkylene group or a phenylene group, and D is a hydrogen atom, a C.sub.1-6 alkyl group or the like which has an inhibitory action on platelet aggregation and is useful as a preventive or therapeutic agent for various thrombotic diseases.

    摘要翻译: PCT No.PCT / JP96 / 02944 Sec。 371日期:1998年4月13日 102(e)1998年4月13日PCT PCT 1996年10月11日PCT公布。 第WO97 / 13757号公报 日本1997年4月17日由通式(I)表示的吡唑啉酮衍生物或其盐:其中X1和X2之一为(其中A为氰基,氰基C1-4烷基,氨基,氨基 C 1-4烷基,脒基或胍基,R 1和R 2独立地为氢原子,卤素原子,C 1-6烷基等),X 1和X 2中的另一个为C 1-6 烷基,C 3-6烯基,芳基C 1-4烷基或芳基,Y1和Y2之一为(其中Q为氧原子或硫原子,Z1为氧原子,-NR7- 基团或-CHR7-基团,Z2为环状C3-7亚烷基,C1-3亚烷基,-CH2CO-基或-CH2CH2CO-基,Z3为氧原子,硫原子,亚磺酰基, 磺酰基等,Z4为C1-3亚烷基,Z5为羧基等,Y1和Y2中的另一个为DE-基[其中E为键,C1-4亚烷基 基团或亚苯基,D为氢原子,C1-6烷基 对血小板聚集具有抑制作用,可用作各种血栓性疾病的预防或治疗剂。

    Pyridazinone derivatives
    8.
    发明授权
    Pyridazinone derivatives 失效
    哒嗪酮衍生物

    公开(公告)号:US5750523A

    公开(公告)日:1998-05-12

    申请号:US676227

    申请日:1996-07-23

    CPC分类号: C07D401/12 C07D237/22

    摘要: Pyridazinone derivatives represented by the formula (I) and antiplatelet agents containing them: ##STR1## �wherein R is a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group, X is a hydrogen atom, a chlorine atom or a bromine atom, Ar is a pyridyl group or a phenyl group substituted with OR.sup.1 (wherein R.sup.1 is a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group) and A {wherein A is a hydrogen atom, a halogen atom, a C.sub.1 -C.sub.4 alkyl group or OR.sup.2 (wherein R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group)}, is C.sub.1 -C.sub.8 alkylene wherein one carbon atom on the straight chain is substituted with one OR.sup.1 group (wherein R.sup.1 is the same as defined above), and Z.sup.1 and Z.sup.2 are independently a hydrogen atom, a halogen atom, a C.sub.1 -C.sub.4 alkyl group or a OR.sup.1 group (wherein R.sup.1 is the same as defined above)!. These compounds have strong antiplatelet effects, are excellently safe, and can be used as active ingredients of prophylactic and therapeutic drugs for various thrombotic diseases.

    摘要翻译: PCT No.PCT / JP95 / 00069 Sec。 371日期:1996年7月23日 102(e)日期1996年7月23日PCT提交1995年1月24日PCT公布。 WO95 / 19969 PCT公开 日期:1997年7月27日由式(I)表示的哒嗪酮衍生物和含有它们的抗血小板剂:其中R是氢原子或C1-C4烷基,X是氢原子,氯原子 或溴原子,Ar是吡啶基或被OR 1取代的苯基(其中R1是氢原子或C1-C4烷基)和A {其中A是氢原子,卤原子,C1-C4 烷基或OR 2(其中R 2是氢原子或C 1 -C 4烷基)}是其中一个碳原子被一个OR 1基团取代的C 1 -C 8亚烷基(其中R 1与上述定义相同) ,Z 1和Z 2独立地为氢原子,卤素原子,C 1 -C 4烷基或OR 1基(其中R 1与上述定义相同)]。 这些化合物具有很强的抗血小板作用,非常安全,可用作各种血栓性疾病的预防和治疗药物的活性成分。

    3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
    10.
    发明授权
    3(2H)pyridazinone, and antagonistic agent against SRS-A containing it 失效
    3(2H)哒嗪酮,和含有它的SRS-A拮抗剂

    公开(公告)号:US4978665A

    公开(公告)日:1990-12-18

    申请号:US144173

    申请日:1988-01-15

    CPC分类号: C07D237/22

    摘要: A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is hydrogen, 2-propenyl or straight chained or branched C.sub.1 -C.sub.4 alkyl; R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl; X is chlorine or bromine; Y is hydrogen, nitro, -NHR.sub.3 wherein R.sub.3 is hydrogen or straight chained or branched C.sub.1 -C.sub.4 alkyl, -AR.sub.4 wherein A is oxygen or sulfur and R.sub.4 is hydrogen, straight chained or branched C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl having one double bond, C.sub.3 -C.sub.6 alkynyl having one triple bond, phenyl or ##STR2## wherein R.sub.5 is hydrogen or C.sub.1 -C.sub.4 alkyl, or halogen; Z.sub.1 is hydrogen, C.sub.1 -C.sub.4 alkyl, -OR.sub.6 wherein R.sub.6 is hydrogen, straight chained or branched C.sub.1 -C.sub.8 alkyl or ##STR3## wherein n is an integer of from 1 to 4, -N(R.sub.7).sub.2 wherein R.sub.7 is C.sub.1 -C.sub.4 alkyl, or halogen; Z.sub.2 is C.sub.1 -C.sub.4 alkyl, -OR.sub.6 wherein R.sub.6 is as defined above, -N(R.sub.7).sub.2 wherein R.sub.7 is as defined above, or halogen, provided that when R.sub.1 is straight chained or branched C.sub.2 -C.sub.4 alkyl, Y is not hydrogen and when R.sub.1 is hydrogen, methyl or 2-propenyl, Y and R.sub.2 are not simultaneously hydrogen, or a pharmaceutically acceptable salt thereof.